menu
    • menu
    [{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"2-hydroxypropyl-beta Cyclodextrin","moa":"Cholesterol efflux","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"University of Miami","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ZyVersa Therapeutics, Inc \/ University of Miami","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ University of Miami"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.01,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"2-hydroxypropyl-beta-cyclodextrin","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ George Clinical","highestDevelopmentStatusID":"6","companyTruncated":"ZyVersa Therapeutics, Inc \/ George Clinical"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZyVersa Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"IC 100-08","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by ZyVersa Therapeutics, Inc

    Menu

    ZyVersa Therapeutics, Inc

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ZyVersa Gets IRB Approval for Phase 2a Trial Of VAR 200 in Diabetic Kidney Disease

                            Details : VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is being developed to mediate removal of excess cholesterol that damages the kidneys’ filtration system in patients with Diabetic Kidney Disease.

                            Brand Name : VAR 200

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 18, 2024

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC 100-08

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $2.7 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            ZyVersa Raises $2.7M as Inflammasome Inhibitors Show Promise for Obesity Treatment

                            Details : The net proceeds will be used to focus on the clinical development of IC 100-08, a novel humanized IgG4 monoclonal antibody. Currently, it is being evaluated in the preclinical studies for obesity.

                            Brand Name : IC 100-08

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 29, 2024

                            Lead Product(s) : IC 100-08

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $2.7 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : George Clinical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator...

                            Details : VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase 2a-ready drug in development which has potential to treat multiple kidney diseases, including diabetic kidney disease, rare kidney diseases, FSGS (focal segmental glomerulosclerosis) and Alp...

                            Brand Name : VAR 200

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 14, 2023

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : George Clinical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support...

                            Details : VAR 200 (2HPβCD) is a cholesterol efflux mediator in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system. VAR 200 passively and actively removes excess lipids from the kidney and has potential to treat other gl...

                            Brand Name : VAR 200

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 03, 2023

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Larkspur Health Acquisition

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing an...

                            Details : The support will enable company to advance clinical evaluation of cholesterol efflux mediator candidate (VAR 200) in patients with orphan renal disease, FSGS, and to progress the inflammasome ASC inhibitor candidate (IC 100) into Phase 1 trials.

                            Brand Name : VAR 200

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 27, 2022

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Larkspur Health Acquisition

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC 100

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Larkspur Health Acquisition Corp

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, I...

                            Details : IC 100, a novel monoclonal antibody inflammasome ASC inhibitor, targets multiple types of inflammasomes, including NLRP1, to block initiation and perpetuation of damaging chronic inflammation.

                            Brand Name : IC 100

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 22, 2022

                            Lead Product(s) : IC 100

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Larkspur Health Acquisition Corp

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC 100

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Larkspur Health Acquisition Corp

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translationa...

                            Details : IC 100, a novel monoclonal antibody inflammasome ASC inhibitor, targets multiple types of inflammasomes to block initiation and perpetuation of damaging chronic inflammation.

                            Brand Name : IC 100

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 03, 2022

                            Lead Product(s) : IC 100

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Larkspur Health Acquisition Corp

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC 100

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : University of Miami

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ZyVersa Therapeutics and University of Miami Awarded a Grant from The Michael J. Fox Foundation to Determine i...

                            Details : IC 100, a CNS-penetrating monoclonal ASC Inhibitor, targets multiple types of inflammasomes to block initiation and perpetuation of damaging chronic inflammation.

                            Brand Name : IC 100

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 27, 2022

                            Lead Product(s) : IC 100

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : University of Miami

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-hydroxypropyl-beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Larkspur Health Acquisition Corp.

                            Deal Size : $7.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ZyVersa Therapeutics to Become a Publicly Traded Biopharma Company via Merger with Larkspur Health Acquisition...

                            Details : ZyVersa's management team has deep scientific and operational experience, and the company has two exciting assets, IC 100 for inflammatory diseases and VAR 200 for renal diseases.

                            Brand Name : VAR 200

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 20, 2022

                            Lead Product(s) : 2-hydroxypropyl-beta Cyclodextrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Larkspur Health Acquisition Corp.

                            Deal Size : $7.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            ZyVersa Therapeutics, Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC 100

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ZyVersa Therapeutics' to Present at the 3rd Annual Chronic Kidney Disease Drug Development Summit Being Held V...

                            Details : ZyVersa is well positioned in the rapidly emerging inflammasome spwith IC 100, and in kidney disease with a first-in-class phase 2a-ready cholesterol efflux mediator for treatment (VAR 200) of orphan renal disease FSGS and other kidney diseases.

                            Brand Name : IC 100

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 26, 2021

                            Lead Product(s) : IC 100

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth